Jazz Pharmaceuticals plc
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $1.07B | $4.43 | $6.34 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | $1.20B | $3.21 | $6.64 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $1.13B | $4.08 | $8.13 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $1.05B | $-11.74 | $-8.25 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $898.00M | $-1.52 | $1.68 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | After market close | $1.09B | $3.11 | $6.60 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $1.05B | $3.42 | $6.61 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Gross margin %GAAP | full year 2026 | 89% to 90% | New |
| Gross margin %non-GAAP | full year 2026 | 90% to 91% | New |
| Weighted-average ordinary shares outstandingGAAP | full year 2026 | 66 to 67 | New |
| Weighted-average ordinary shares outstandingnon-GAAP | full year 2026 | 66 to 67 | New |
| Effective tax rateGAAP | full year 2026 | 0% to 10% | New |
| Effective tax ratenon-GAAP | full year 2026 | 11.5% to 13.5% | New |
| SG&A expensesGAAP | full year 2026 | $1.42B to $1.50B | New |
| R&D expensesGAAP | full year 2026 | $811.00M to $867.00M | Lowered |
| SG&A expensesnon-GAAP | full year 2026 | $1.26B to $1.32B | New |
| R&D expensesnon-GAAP | full year 2026 | $725.00M to $775.00M | Lowered |
| Total Revenues | full year 2026 | $4.25B to $4.50B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Jazz Pharmaceuticals filed with the SEC
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Regulation FD disclosure · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala,
Results of operations · EX-99.1 to Form 8-K
Phase 3 Results Support Ziihera ® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Innovating to Transform the Lives of Patients and Their Families Markella ® EPIDIOLEX patient diagnosed with Dravet syndrome January 2025
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces U.S. FDA Approval of
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Private Offering of $850 Million of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Pricing of Private Offering of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Conference Innovating to Transform the Lives of Patients and Their Families Caroline ® January 2024 Rylaze patient diagnosed with ALL / LBL
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
41st Annual J.P. Morgan Healthcare
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement
Other events · EX-99.1 to Form 8-K
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi ® (solriamfetol) to Axsome
Other events · EX-99.1 to Form 8-K